Effectiveness of Myopia Control Interventions : A Comparison of Myopia Control in European Children, Adolescents and Young Adults With Defocus Incorporated Multiple Segments (DIMS) and Highly Aspherical Lenslets (HAL) Spectacles, Atropine, Lenses and Combined Treatments
Key facts
- Who runs it
- Centre Hospitalier Universitaire de Saint Etienne
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 114 people enrolled
- Started
- 20 Oct 2024
- Ended
- 7 May 2025
- Type of study
- Observational, 3 groups
- Treatments tested
- Demographic data collection
- Ophthalmological history
- Ophthalmological data at each examination
- Potential adverse events
- Record updated
- 13 August 2025
Who can take part
- Age
- Up to 25 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Children or young adults with active myopia treated with ATROPINE 0.01% eye drops or myopia control glasses or contact lenses, and their various combinations
- patient affiliated with a social security organization
- agreement of both parents or the patient if adult
Who cannot take part
- non compliance with treatment
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The prevalence of myopia and its complications has risen considerably in recent decades, particularly among children and teenagers. This trend is also spreading in Europe, driven by the increase in screen time and the intensive use of new technologies and social media, particularly among the younger generation.
Read full original descriptionShow less
Several treatment options are available today, including pharmacological treatments with atropine eye drops, as well as optical myopia control systems in the form of glasses or contact lenses.
These different treatments have been used in clinical practice at Saint-Étienne University Hospital since 2017 for atropine, and more recently with the development of optical myopia control systems and their combinations.
Little clinical data has been published to date on these different treatment combinations in the French population.
The investigators would therefore like to set up a database to publish their results and share their experience.
The 3 groups in the trial
- Atropine 0.01%
Children or young adults with active myopia treated with ATROPINE 0.01% eye drops.
Treatment: Demographic data collection, Ophthalmological history, Ophthalmological data at each examination, and Potential adverse events
- DIMS/HAL
Children or young adults with active myopia treated with myopia control glasses.
Treatment: Demographic data collection, Ophthalmological history, Ophthalmological data at each examination, and Potential adverse events
- Various combined treatments
Children or young adults with active myopia treated with ATROPINE 0.01% eye drops or myopia control glasses or contact lenses, and their various combinations.
Treatment: Demographic data collection, Ophthalmological history, Ophthalmological data at each examination, and Potential adverse events
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 13 August 2025